Common stocks of Haim Bio are issued as uniform stocks and are currently traded on the over-the-counter market. If you are interested in investing in the company, please acquire common stocks from the over-the-counter market.

The company stocks are uniform stocks that are readily traded on the over-the-counter market. Therefore, you are considered to be listed in the shareholder list once your purchased stocks are deposited in the security account.

We do not currently have plans to increase capital, but once we have future plans to increase capital, the plans will be published on the company website after the decision of the BOD. In case of capital increase by allocation to stockholder, the decision will be published on the company website and notified to individual shareholder.

The timing is unknown, but the company will be enlisted by considering the progress in nonclinical and clinical experiments. If we see successful results from phase 1 or 2 clinical test according to plan, we expect to list in 2020.

This technology induces the destruction of cancer cells by lowering the metabolic energy of cancer cells by using NYH817G and NYH100P as active ingredients.

The metabolic anti-cancer drug being developed by Haim Bio by using NYH817G and NYH100P as the active ingredients is being developed first in the whole world by selectively interrupting the energy metabolism of cancer cells.

We are currently under the nonclinical test, which is expected to be completed in late 2018 or early 2019 if it goes in plan. Based on the results, we plan to file for the clinical test for Investigational New Drugs (IND) in 2019.

The patent related with polyphosphate has been transferred in the Q1 2016. It has a wide range of use from pharmaceutical products to health supplements and beauty products, and we plan to develop related products in the future.